2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 116

The Effect of the Formal Approval of Colchicine on Utilization of Emergency Department and Rheumatology Outpatient Services By Patients with Gout
Abstract Number: 1561

The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Abstract Number: 975

The Effect of TNF Inhibition on Radiographic Progression in Ankylosing Spondylitis: An Observational Cohort Study of 374 Patients
Abstract Number: 973

The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register
Abstract Number: 2273

The Effect of Widespread Pain on Incident Knee Pain and Knee Osteoarthritis: The Multicenter Osteoarthritis (MOST) Study
Abstract Number: 1193

The Effectiveness of Low-Impact Exercise Program on Musculoskeletal Health of Asian Older Adults
Abstract Number: 2360

The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease
Abstract Number: 2923

The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus
Abstract Number: 2690

The Effects of Disease of the Joints on Modified Health Assessment Questionnaire Scores in Rheumatoid Arthritis Patients: A Retrospective Study Using the National Database of Rheumatic Diseases By Ir-Net in Japan
Abstract Number: 1634

The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Abstract Number: 3026

The Effects of Lrg on the Differentiation of Naïve T Cells
Abstract Number: 368

The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
Abstract Number: 2349

The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Abstract Number: 834

The Efficacy of Rituximab in Systemic Sclerosis Joint Disease: A Pilot Study
Abstract Number: 2953

The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].